IP Library Granted Patent US 7,375,252
Granted Patent B2
US 7,375,252 · App. 10/114,351 · Granted May 20, 2008

Compounds and method for the inhibition of the expression of VCAM-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,252
App. No.
10/114,351
Granted
May 20, 2008
Kind
B2
Abstract

This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Claims (15)

1. A compound of the formula

or a pharmaceutically acceptable salt or ester thereof.

2. A compound of the formula

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of the formula

together with a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for oral administration.

5. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for topical administration.

6. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

7. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for subcutaneous administration.

8. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for intraperitoneal administration.

9. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for intramuscular administration.

10. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for submucosal administration.

11. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for inhalation administration.

12. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is suitable for transdermal administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: ATHEROGENICS, INC.
To: CRABTREE ACQUISITION CO, LLC
Reel/Frame 024933/0616 →
CHANGE OF NAME Recorded Sep 3, 2010
From: CRABTREE ACQUISITION CO, LLC
To: SALUTRIA PHARMACEUTICALS LLC
Reel/Frame 024933/0651 →